TGFBR2 and cancer: The significantly mutated genes in the hypermutated cancers included ACVR2A (63 %), APC (51 %), TGFBR2 (51 %), BRAF (46 %), MSH3 (40 %), MSH6 (40 %), MYOB1 (31 %), TCF7L2 (31 %), CASP8 (29 %), CDC27 (29 %), FZD3 (29 %), MIER3 (29 %), TCERG1 (29 %), MAP7 (26 %), PTPN12 (26 %) and TP53 (20 %).